Treg Modulation With CD28 and IL-6 Receptor Antagonists
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of using lulizumab pegol with
tocilizumab, belatacept, and everolimus in kidney transplant recipients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Bristol-Myers Squibb Clinical Trials in Organ Transplantation